efficacy and safety of febuxostat and allopurinol - Wiley Online Library
Recommend Documents
Oct 26, 2018 - recipients with new onset of hyperuricemia receiving febuxostat or ...... slowing the GFR decline in patients with CKD and asymptomatic.
Moldova; 3Oleksandr Voloshyn, MD: Chernivtsi Regional Clinical. Hospital, Chernivtsi .... hoc test. RESULTS. Patient disposition and baseline demographics.
bCalifornia National Primate Research Center, University of California, Davis, ... dInstitute for Global Health, University of California, San Francisco 94105,.
Dec 27, 2013 - Novartis-Orion, GSK, UCB and Merck-Serono. Dr Barone has received compensation for consulting services and/or research support from Bo-.
100mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no ... thiazolidinediones can be added as second agents [1,2].
May 19, 2011 - Hospital Los Angeles, Los Angeles, CA, USA ... Oakland, 747 52nd Street, Oakland, CA 94609,. USA. E-mail: .... History of splenectomy, n (%).
Arno W. Hoes,1 Jan Jaap van der Net,1 Carla Engels,1 Wietse Kuis,1 Berent J. ..... Offit PA, Hackett CJ. .... Park CL, Frank AL, Sullivan M, Jindal P, Baxter BD.
Jun 1, 2017 - Jason Lobo M.D., 8006 Burnett- .... Glendale, CA, https://www.denovosoftware.com). .... gen, Germantown, MD, https://www.qiagen.com).
Feb 6, 2017 - lixisenatide has also been shown for liraglutide, a long-acting GLP-1 ... In a 52-week extension, liraglutide monotherapy treatment (0.9 mg/day).
aTotal numbers (%) of patients classified as 'Asian', 'Native Hawaiian or Other Pacific Islander', and 'Other' were 9 (4.8), 4 (2.1), and 4 (2.1), respectively.
What is the best skin disinfectant solu- tion for labour ... Chichester, UK. Email: [email protected] ... patient, who had a body mass index of over 30 kg.m.
efficacy and safety of febuxostat and allopurinol - Wiley Online Library
Diabetes and gout: efficacy and safety of febuxostat and allopurinol M. A. Becker1 , P. A. MacDonald2 , B. J. Hunt2 & R. L. Jackson2 1 Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA 2 Takeda Global Research & Development Center, Inc., Deerfield, IL, USA
Aim: Assess influences of demographics and co-morbidities of gout patients with or without diabetes on safety and efficacy of urate-lowering agents.
Methods: Post-hoc analysis of 312 diabetic and 1957 non-diabetic gout patients [baseline serum urate levels (sUA) ≥8.0 mg/dl] enrolled in a 6-month randomized controlled trial comparing urate-lowering efficacy (ULE) and safety of daily xanthine oxidase inhibitors (XOIs) febuxostat (40 mg or 80 mg) and allopurinol (200 mg or 300 mg). We compared baseline demographic, gout and co-morbid characteristics, ULE, and safety of XOI treatment in diabetic and non-diabetic gout patients. ULE was measured by the proportion of diabetic and non-diabetic patients in each treatment group achieving final visit sUA < 6.0 mg/dl. Safety was monitored throughout the trial. Results: Diabetic gout patients were older, more frequently female, and had longer gout duration. Co-morbidities were more frequent among diabetic patients: cardiovascular disease; impaired renal function; hyperlipidemia; and obesity (body mass index >30 kg/m2 ) (p < 0.001 for all comparisons). Febuxostat 80 mg ULE exceeded that of febuxostat 40 mg or allopurinol (p < 0.050) at all levels of renal function, achieving sUA goal range in the majority of diabetic and non-diabetic patients. Diabetics and non-diabetics reported self-limiting diarrhoea and URIs as the most common adverse events. Conclusions: Despite higher co-morbidity rates in diabetic patients, febuxostat and allopurinol were safe in both groups at the doses tested. Febuxostat 80 mg achieved sUA
